Atea Pharmaceuticals Capital Expenditures (CapEx) Growth & History (AVIR)

Atea Pharmaceuticals's capital expenditures (capex) was $1.9M for fiscal 2022.

View full Atea Pharmaceuticals company overview

Atea Pharmaceuticals annual capital expenditures (capex) history

Atea Pharmaceuticals annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20222022-12-31$1.9M$1.9M+48475.00%
20212021-12-31$4,000−$22,000−84.62%
20202020-12-31$26,000$24,000+1200.00%
20192019-12-31$2,000−$10,000−83.33%
20182018-12-31$12,000

Atea Pharmaceuticals capital expenditures (capex) trends

Between the periods ended 2018-12-31 and 2022-12-31, Atea Pharmaceuticals's capital expenditures (capex) increased from $12,000 to $1.9M, a change of $1.9M. The latest reported quarter, Q4 2022, shows $0.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

SEC-reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Atea Pharmaceuticals source filings ↗

Community posts

It’s quiet here.

No posts about AVIR yet. Start the conversation.

Write the first post